ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

BG Medicine Withdraws IPO After Failing To Price All Week

DOW JONES NEWSWIRES Diagnostic-test maker BG Medicine Inc. withdrew its planned initial public offering Thursday, after the deal failed to price all week long. The company, which focuses on blood-based tests, had planned to offer at least 4.8 million shares in an estimated price range of $13 to $15. Those terms were scaled back from its initial plan in January, when it registered to sell up to an estimated $86.3 million of stock. This, the year's final week of IPO issuance in the U.S., has been marked by heavy volume and weak pricings on the whole as companies struggle to finish deals before a winter hiatus. BG Medicine's lead product, a test for heart failure, was slated to launch this month in a manual model, after it received clearance from the Food and Drug Administration in November. The company, however, has said an automated version is necessary for it "to achieve broad customer acceptance and clinical adoption." It has partnerships with Abbott Laboratories (ABT), Alere Inc. (ALR) and bioMerieux SA (BIM.FR) to include the heart-failure test on a variety of automated lab instruments, and it plans to apply for FDA clearance for it no later than the fourth quarter next year. It had planned to use proceeds from the IPO to help launch the test, as well as for development of other products. It also said it may have used the money for possible technology acquisitions. Like many development-stage companies in health care, BG has never been profitable. According to filings with the Security and Exchange Commission, it expects to post losses for the next several years. In the first nine months of this year, BG Medicine's loss widened because of higher interest expense. The company was slated to have about 18 million shares outstanding after the IPO. It was going to list on the Nasdaq Global Market under the symbol BGMD. -By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; joan.solsman@dowjones.com

Stock News for Abbott Labs (ABT)
DateTimeHeadline
08/26/201613:42:00Alere Sues Abbott to Force Merger -- 2nd Update
08/26/201613:11:00Alere Sues Abbott to Force Merger -- Update
08/26/201612:50:00Alere Sues Abbott to Force Merger
08/26/201612:47:00Alere Sues Abbott Laboratories to Force Merger
08/24/201609:00:00Abbott to Present at Wells Fargo Healthcare Conference
08/17/201602:09:05Aqua Bio Technology: Stable revenues, results affected by U.S...
08/09/201616:53:26Registration Statement for Securities to Be Issued in Business...
08/03/201616:35:50Quarterly Report (10-q)
08/02/201610:00:00Abbott Unveils Alinity™, its Unified Family of Innovative Next-Generation D...
07/29/201617:06:14Statement of Changes in Beneficial Ownership (4)
07/29/201617:05:18Statement of Changes in Beneficial Ownership (4)
07/29/201610:40:00AbbVie Results Boosted by Humira, Pipeline Growth
07/29/201610:31:00AbbVie Results Boosted by Humira, Pipeline Growth
07/28/201608:10:00China's Fosun Close to Deal for India's Gland Pharma
07/28/201603:03:00Alere Faces Criminal Probe Over Billing -- WSJ
07/27/201618:57:00Alere Faces Criminal Probe Over Medicare, Medicaid Billing...
07/27/201617:14:00Alere Faces Criminal Probe Over Medicare, Medicaid Billing...
07/27/201617:10:00Alere Faces Criminal Probe Over Medicare, Medicaid Billing
07/27/201616:45:54Statement of Changes in Beneficial Ownership (4)
07/27/201616:45:04Statement of Changes in Beneficial Ownership (4)

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad